Nutrition21 Presents The Proteomic Results Of A Nitrosigine Clinical Study at 2015 Annual Meeting
Nutrition 21, LLC (“Nutrition 21”) is proud to announce the presentation of new clinical study results supporting the efficacy of Nitrosigine® bonded arginine silicate (ASI), titled, “Arginine Silicate Supplementation Decreases Markers of Cardiovascular, Renal and Metabolic Dysfunction and Increases Markers of Vasodilation and Cardiovascular Health in Healthy Adult Males.”
Nitrosigine®, Velositol®, nooLVL®, Chromax®, Lepidamax®, Zinmax®, and their associated logos are registered trademarks of Nutrition21, LLC. All third party trademarks are the property of their respective owners. Nutrition21, LLC's products are protected by a number of patents including, but not limited to: US Patent Nos. 6,809,115; 6,803,456; 7,576,132; 8,062,677; 8,933,022; 9,005,637; 9,028,879; 9,119,835; 9,421,170; 9,597,404; 9,675,702; 10,183,049; 10,245,325; and 10,363,222.
These statements have not been evaluated by the Food and Drug Administration. These products are not intended to diagnose, treat, cure, or prevent any disease.